Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|June 15, 2016
Potential Impact of Regorafenib in Patients With HCC
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).
Advertisement
Advertisement
Related to this article
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5